NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Monday that its fourth-quarter revenues increased sharply as its net loss climbed on a change in fair value of derivative instruments related to warrants.

The San Diego-based molecular diagnostics developer brought in total revenues of $163,000 for the three months ended Dec. 31, compared to $34,000 for the fourth quarter of 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.